{
    "Trade/Device Name(s)": [
        "EliA RF IgM Immunoassay",
        "EliA RF IgA Immunoassay",
        "EliA RF Positive Control 100",
        "EliA RF Positive Control 250"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K102673",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHR",
        "JJY"
    ],
    "Summary Letter Date": "September 30, 2011",
    "Summary Letter Received Date": "August 30, 2011",
    "Submission Date": "August 29, 2011",
    "Regulation Number(s)": [
        "21CFR866.5775",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Rheumatoid factor immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "Rheumatoid factor IgM",
        "Rheumatoid factor IgA"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Li-heparin tube",
        "EDTA tube",
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Phadia 100",
        "Phadia 250"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence Immunoassay",
        "ELISA"
    ],
    "Methodologies": [
        "Fluorescence Immunoassay",
        "Non-competitive solid phase immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for EliA RF IgM/IgA Immunoassay and Positive Controls for detection and monitoring of rheumatoid factor using Phadia 100/250 automated immunoassay platforms.",
    "Indications for Use Summary": "Intended for the in vitro semi-quantitative measurement of IgM or IgA class rheumatoid factor antibodies in human serum and plasma to aid in the diagnosis of rheumatoid arthritis, and for controls to monitor assay performance on Phadia 100 and 250 instruments.",
    "fda_folder": "Immunology"
}